Research Paper Volume 12, Issue 23 pp 23578—23597

Figure 1. Development of B and T lymphocytes in Xlf^-/-Mri^-/-Trp53^+/- mice. (A) Number of thirty-day-old mice (P30) of indicated genotypes. *Expected distribution assuming lethality. (B) Comparison of body size, thymi and spleens of XLF/MRI-deficient and XLF-deficient mice of the same age. (C) Weights of WT, Xlf^-/-, Mri^-/-, Xlf^-/-Mri^-/-Trp53^+/- mice. (D, E) Number (×10⁶) of thymocytes (D) and splenocytes (E) in WT, Xlf^-/-, Mri^-/-, Xlf^-/-Mri^-/-Trp53^+/- mice. (F) Flow cytometric analysis of thymic and splenic T cell subsets and splenic B cells. (G, H, I) Number (×10⁶) of splenic CD19+ B cells (G), splenic CD3+ T cells (H) and thymic CD4+CD8+ double positive (DP) T cells (I) in WT, Xlf^-/-, Mri^-/-, Xlf^-/-Mri^-/-Trp53^+/-, Paxx^-/-, Xlf^-/-Paxx^-/-Trp53^+(-)/- and Paxx^-/-Mri^-/- mice. Dna-pkcs^-/- mice were used as an immunodeficient control. Comparisons between every two groups were made using one-way ANOVA, GraphPad Prism 8.0.1. Xlf^-/-Paxx^-/-Trp53^+(-)/- is a combination of Xlf^-/-Paxx^-/-Trp53^+/- and Xlf^-/-Paxx^-/-Trp53^-/-. Not shown in the graph for (G): WT vs Paxx^-/-Mri^-/-, p<0.0001 (****), Paxx^-/- vs Paxx^-/-Mri^-/-, p<0.0001 (****), Mri^-/- vs Paxx^-/-Mri^-/-, p<0.0025 (**), Xlf^-/- vs Paxx^-/-Mri^-/-, p=0.9270 (n.s), Xlf^-/-Mri^-/-Trp53^+/- vs Paxx^-/-Mri^-/-, p<0.0001 (****), and Xlf^-/-Paxx^-/-Trp53^+(-)/- vs Paxx^-/-Mri^-/-, p<0.0001 (****).